SAGE | Sage Therapeutics, Inc. Stock Overview

(Stock Exchange: NASDAQ)

Day's Range	4.95 - 5.62
52 Week Range	4.62 - 28.26
Beta	0.28
Implied Volatility	124.36%
IV Rank	46.89%
Day's Volume	4,148,019
Average Volume	821,601
Shares Outstanding	61,173,300
Market Cap	343,182,213
Sector	Healthcare
Industry	Biotechnology
IPO Date	2014-07-18

Valuation
Profitability
Growth
Health
P/E Ratio	-1.01
Forward P/E Ratio	-3.95
EPS	-5.57
1YR Price Target	48.00
Dividend Yield	N/A
Dividend Per Share	N/A
Dividend ExDate	N/A
Dividend PayDate	N/A
Employees	487
Country	USA
Website	SAGE

Sage Therapeutics Inc is a clinical-stage biopharmaceutical company focused on the study of the nervous system and brain to discover medicines to treat life-threatening, rare central nervous system disorders. The company's lead development program is SAGE-217 program which is in Phase 3 clinical trials for post-partum depression, essential tremor, Parkinson's disease, and major depressive disorder. The company is also developing several other compounds for treatment that are in the early stage of development.

SAGE's peers: APLS, TERN, DAWN, BPMC, CERE, MRTX, AMLX, RLAY, STOK, PLRX, BDTX, ARVN, KRYS, ALNY, MDGL, INCY, RETA, DMAC, AKRO, NUVL, IMCR, VTYX, VALN

*Chart delayed

Analyzing fundamentals for SAGE we got that it has weak fundamentals where Valuation is considered to be significantly overvalued, Profitability is unacceptably poor, Growth is desperately bad and Health is weak. For more detailed analysis please see SAGE Fundamentals page.

Watching at SAGE technicals we can see that long-term trend is bearish, the same as bearish middle-term trend, but short-term trend is bullish. More technicals details can be found on SAGE Technicals page.